The German Roentgen Society (DRG) and the German Society for Neuroradiology will host an online education session that aims to update radiologists and neuroradiologists about new Alzheimer's disease therapies.
This follows the EU's approval of two new anti-amyloid antibodies, Lecanemab and Donanemab, which aim to slow disease progression. However, these are not intended to be cures for Alzheimer's.
The session, "New Alzheimer's Therapies - Radiological Accompanying Phenomena in Focus," will provide a practical overview of typical MRI findings, image morphological progression, and risk factors for amyloid-related imaging abnormalities (ARIAs). It will use numerous case studies and participants will receive tips on standardized diagnostics, differential diagnosis, and reliable assessment of the progression.
Prof. Elke Hattingen, PhD, director of the Department of Neuroradiology at the University Hospital Frankfurt am Mainfrom Goethe-University Frankfurt, will be the main speaker. Also, the DRG has posted an interview with Hattingen on this topic.
Find out more about the lecture here.
